Compare TAYD & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAYD | BDTX |
|---|---|---|
| Founded | 1955 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.7M | 171.9M |
| IPO Year | 1995 | 2020 |
| Metric | TAYD | BDTX |
|---|---|---|
| Price | $53.60 | $1.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $70.00 | $9.67 |
| AVG Volume (30 Days) | 47.3K | ★ 1.6M |
| Earning Date | 03-31-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.24 | ★ 130.71 |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $46,292,725.00 | N/A |
| Revenue This Year | $0.25 | N/A |
| Revenue Next Year | $19.78 | N/A |
| P/E Ratio | $18.63 | ★ N/A |
| Revenue Growth | ★ 3.84 | N/A |
| 52 Week Low | $40.50 | $1.60 |
| 52 Week High | $90.37 | $4.94 |
| Indicator | TAYD | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 42.31 |
| Support Level | $53.46 | $1.76 |
| Resistance Level | $61.21 | $2.26 |
| Average True Range (ATR) | 2.53 | 0.11 |
| MACD | -0.39 | 0.01 |
| Stochastic Oscillator | 11.66 | 6.17 |
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.